Agenus To Present At OneMedForum San Francisco 2013

LEXINGTON, Mass., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the 6 th Annual OneMedForum San Francisco 2013, which will be held at the Sir Francis Drake Hotel in San Francisco.

Dr. Garo Armen, Chairman and CEO of Agenus, will present a corporate overview on Tuesday, January 8 th at 9:40 am PST in the Franciscan Room.

Between Agenus and its partners, 19 programs are in clinical development. Agenus' QS-21 Stimulon ® adjuvant 1 is being studied in clinical trials for 17 vaccine indications. They include:
  • Phase 3: GSK's RTS,S for malaria 2
  • Phase 3: GSK's MAGE-A3 for non-small cell lung cancer 2
  • Phase 3: GSK's MAGE-A3 for melanoma 2
  • Phase 3: GSK's Zoster Herpes for shingles 2
  • Phase 2: Janssen's ACC-001 for Alzheimer's disease

Agenus pipeline programs include:
  • Phase 2: Prophage Series G-100 for newly diagnosed glioma
  • Phase 2: Prophage Series G-200 for recurrent glioma
  • Phase 2 : HerpV (contains QS-21 Stimulon) for genital herpes

Saponin Platform: QS-21 Stimulon ® Adjuvant

Agenus' licensees include GlaxoSmithKline and Janssen Alzheimer Immunotherapy. Agenus is generally entitled to receive milestone payments as QS-21-containing programs advance, as well as royalties for 10 years after commercial launch, with some exceptions.

Heat Shock Protein Platform: Prophage Series G

The Prophage Series G vaccines (HSPPC-96; vitespen) are being studied in two different settings of glioma: newly diagnosed and recurrent disease. Glioma is the deadliest form of brain cancer with an average survival of six to 14 months.

Heat Shock Protein Platform: Recombinant Series HerpV                                                                                                        

HerpV is the most advanced HSV-2 vaccine currently in clinical development for the treatment of genital herpes. A Phase 2 study measuring the effect of vaccination on viral shedding in individuals infected with HSV-2 is underway. Data results for this study are anticipated in Q4'13. Experts in HSV-2 clinical research believe that a reduction in viral shedding could translate into the clinical benefit of a reduction in recurrent outbreaks.

If you liked this article you might like

Market's Trading Range Loosens Up

These 5 Stocks Under $10 Could Ignite Soon

These 5 Stocks Under $10 Could Explode Up Soon

Bullish and Bearish Reversals for the Week

4 Momentum Stocks You Should Watch Now